Haemonetics Corp

HAE remains in a solid medium-term uptrend anchored by price above the 50- and 200-day SMAs, but short-term EMAs have flattened in a narrow consolidation. The lack of a clear breakout or breakdown suggests waiting for confirmation before new entries. We will stalk pullbacks into the converging 9- and 20-day EMA zone near recent support to align with the Stage 2 advance framework.

• ↑Q1 2027 revenue $339M (+6% YoY); adj. EPS $1.14 (+4%) beat consensus
• ↑Raised fiscal 2027 organic growth guidance to 4%–7%
• ↓Gross margin declined to 60.4% due to software license impacts and cost pressures